Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma
Latest Information Update: 24 Sep 2019
At a glance
- Drugs Ramucirumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 14 Jul 2012 Additional trial location (United Kingdom) identified as reported by European Clinical Trials Database.
- 14 Jul 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-006713-16).